Vivoryon Therapeutics N.V. (VIE:VVYN)

Austria flag Austria · Delayed Price · Currency is EUR
1.526
-0.070 (-4.39%)
At close: Jan 8, 2026
-21.74%
Market Cap45.90M
Revenue (ttm)n/a
Net Income (ttm)-12.48M
Shares Outn/a
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1,142
Open1.594
Previous Close1.596
Day's Range1.518 - 1.594
52-Week Range1.406 - 1.988
Betan/a
RSI49.94
Earnings DateApr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 14
Stock Exchange Vienna Stock Exchange
Ticker Symbol VVYN
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.